Metastatic Castration-resistant Prostate Cancer Clinical Trials in Myrtle Beach, South Carolina

10 studies are recruiting for metastatic castration-resistant prostate cancer in Myrtle Beach, South Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

   The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics - Carolinas, Myrtle Beach, South Carolina

   Locations

   155 in total

   Run by

   Amgen

   See if you can join NCT07213674 on ClinicalTrials.gov

2. A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

   Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Carolina Urologic Research Center, Myrtle Beach, South Carolina

   Locations

   54 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07005154 on ClinicalTrials.gov

3. A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

   This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) w…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Carolina Urologic Research Center, Myrtle Beach, South Carolina

   Locations

   48 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07287150 on ClinicalTrials.gov

4. AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

   The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Myrtle Beach, South Carolina

   Locations

   132 in total

   Run by

   AstraZeneca

   See if you can join NCT07611110 on ClinicalTrials.gov

5. A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

   This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AUC Urologists, LLC, Myrtle Beach, South Carolina

   Locations

   236 in total

   Run by

   Pfizer

   See if you can join NCT06629779 on ClinicalTrials.gov

6. A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

   The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior secon…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Carolina Urologic Research Center, Myrtle Beach, South Carolina

   Locations

   23 in total

   Run by

   Kyntra Bio

   See if you can join NCT06842498 on ClinicalTrials.gov

7. A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

   The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRP…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Carolinas, Myrtle Beach, South Carolina

   Locations

   10 in total

   Run by

   Flare Therapeutics Inc.

   See if you can join NCT07719361 on ClinicalTrials.gov

8. A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

   Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the drug is safe, increasing doses alone and in combination with darolutamide, whether it is effective …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina Urologic Research Center, the START Center for Cancer Research, Myrtle Beach, South Carolina

   Locations

   13 in total

   Run by

   K36 Therapeutics, Inc.

   See if you can join NCT07103018 on ClinicalTrials.gov

9. A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

   This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina Urologic Research Center, Myrtle Beach, South Carolina

   Locations

   19 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT07244341 on ClinicalTrials.gov

10. A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

    Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their can…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Carolina Urologic Research Center, Myrtle Beach, South Carolina

    Locations

    25 in total

    Run by

    Astellas Pharma Global Development, Inc.

    See if you can join NCT04729114 on ClinicalTrials.gov